P010 Relationship Between EGFR and KRAS Mutation and the Clinicopathologic Features of Early Lung Adenocarcinoma

1 Analyze the common driving genes of patients with lung adenocarcinoma at different stages. 2 Analyze the relationship between gene mutation abundance and general clinical data. 3 Analyze The relationship between EGFR and KRAS gene mutation and general clinical characteristics in lung adenocarcinoma. 4 Analyze the relationship between different pathological subtypes of lung adenocarcinoma and gene mutation. A total of 66 cases of lung adenocarcinoma from May 2014 to October 2016 were collected from The Fourth Hospital of Hebei Medical University. The clinical stages were Ⅰ A to Ⅲ B. Next generation sequencing (NGS) was used to detect the mutation status of lung cancer related driving gene. 1 Relationship between the pathological subtype of lung adenocarcinoma and EGFR mutation: the most common pathological subtype in this study was acinar adenocarcinoma, followed by solid adenocarcinoma, then papillary adenocarcinoma, lepidic growth, and invasive mucinous adenocarcinoma. Acinar adenocarcinoma had the highest rate of EGFR mutation, followed by papillary adenocarcinoma, lepidic growth type adenocarcinoma, solid type. Invasive mucinous adenocarcinoma did not show EGFR mutation. Statistically significant differences in EGFR mutation rate were found between histological and pathological subtypes (P<0.05). 2 There were significant differences between KRAS mutation and invasive adenocarcinoma types (P<0.05). Moreover, the mutation rate was higher in invasive mucinous adenocarcinoma. 3 The relationship between EGFR mutation abundance and clinical features: taking 20% mutation abundance as cutoff value, the mutation abundance of EGFR showed no significant difference with neither of the following: gender (P=0.0.246), age (P=0.453), smoking history (P=1.00), tumor stage (Z=-0.500, P=0.617). 1 The rate of EGFR mutation is significantly different among different pathological subtypes of lung adenocarcinoma. The frequency of EGFR mutation is higher in acinar and papillary adenocarcinoma, while lower in invasive mucinous adenocarcinoma. The mutation rate of KRAS was higher in invasive mucinous adenocarcinoma. To sum up, the relationship between the mutation status of the driving gene and the pathological subtype of lung adenocarcinoma is not very clear. This study provides a novel perspective for the following exploration of the correlation between pathological subtypes, stages and other clinical data and the mutation status. 2 In lung adenocarcinoma, the mutation abundance of EGFR gene was not significantly associated with age, gender, tumor stage, and smoking history. 3 Next generation sequencing technology can rapidly, sensitively and accurately detect the mutation status and abundance of EGFR, KRAS and other genes.